Victoza Injection
Product Images NDC 50090-4503

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Victoza (NDC 50090-4503). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1: Structural Formula Of Liraglutide (49f302f5 F315 48b8 83a4 6ca56f01fded 01)

Chemical structure diagram showing the sequence of amino acids in liraglutide with a C-16 fatty acid (palmitoyl) attached. The amino acids are illustrated in circles connected in a chain, representing the peptide sequence of the active ingredient in Victoza injection 6 mg/mL by A-S Medication Solutions.*

FDA Label Image

Figure 2 Mean Insulin Secretion Rate (isr) Versus Glucose Concentration (49f302f5 F315 48b8 83a4 6ca56f01fded 02)

A line graph comparing insulin secretion rates (ISR) in pmol/kg/min versus plasma glucose levels in mg/dL between Victoza and placebo groups. Victoza data points, represented by dark diamonds, show higher ISR across increasing glucose levels compared to the placebo, indicated by gray triangles.*

FDA Label Image

Figure 4 Mean Hba1c For Patients Who Completed The 26-week Trial And For The Last Observation Carried Forward (locf, Intent-to-treat) Data At Week 26 (49f302f5 F315 48b8 83a4 6ca56f01fded 04)

A line graph comparing mean HbA1c (%) levels over 26 weeks for Victoza 1.2 mg, Victoza 1.8 mg, and Sitagliptin 100 mg. The x-axis represents time in weeks, and the y-axis shows mean HbA1c percentages. Two Victoza dosages show a reduction in HbA1c over time, while Sitagliptin remains relatively flat. Statistical significance is noted with a p-value less than 0.0001 for Victoza compared to Sitagliptin.*

FDA Label Image

Victoza Pen And Needle (Image 01)

An instructional diagram showing the components of a Victoza pen injection device with labeled parts including the pen cap, rubber stopper, cartridge tip, cartridge scale, cartridge, dose selector, dose display, pointer, and dose button. It also includes parts of the needle: outer needle cap, inner needle cap, needle, and protective tab. A flow check symbol is shown separately.*

FDA Label Image

Fig. A (Pull off pen cap)

An instructional diagram showing a close-up of a hand gripping the blue cap of a pen-like injection device, with an arrow indicating the cap being pulled off. This illustration is part of the usage directions for the Victoza (liraglutide) injection pen.*

FDA Label Image

Fig. B (Remove protective tab.)

An instructional illustration showing a close-up of a hand holding a Victoza injection pen. The image depicts the user preparing the pen for use by twisting the dial, indicated by a curved arrow pointing upward and around the pen top.*

FDA Label Image

Fig. C And D (- Image 04)

Illustration showing hands removing protective caps from an injection pen needle. The sequential steps labeled C and D depict the first cap being pulled off and then the second cap being removed, preparing the subcutaneous injection device for use.*

FDA Label Image

Fig. E (Image 05)

An instructional illustration showing the flow check symbol selected on a Victoza (liraglutide) injection pen. The image highlights pressing or turning the pen component, with an inset close-up of the flow check symbol on the pen's dosage selector.*

FDA Label Image

Fig. F (Image 06)

An instructional illustration showing a close-up of a person's hand holding a Victoza injection pen with the needle cap being removed. The image emphasizes careful handling of the pen before subcutaneous injection.*

FDA Label Image

Fig. G (Image 07)

An instructional illustration showing how to prepare the Victoza injection pen (liraglutide). It depicts a hand gripping the bottom part of the pen and pulling downward, with a close-up inset highlighting the device's dose display showing '0 mg' and a connector tip detail.*

FDA Label Image

Fig. H (Pull off pen cap.)

An instructional illustration showing a person's hands preparing a subcutaneous injection device, likely for Victoza (liraglutide) injection. It depicts pulling or removing a cap from the injection pen by grasping the pen and pulling the cap upwards, indicated by a directional arrow.*

FDA Label Image

Fig. I (Image 09)

An instructional illustration showing a hand holding a Victoza injection pen and twisting the cap to remove it. A number '1' in the upper left corner suggests this is the first step in a usage or preparation guide.*

FDA Label Image

Fig. J-k (Image 10)

An instructional illustration showing two steps labeled J and K for preparing a Victoza 6 mg/mL subcutaneous injection pen. Step J depicts twisting off a pen cap, and step K shows pulling off a needle cap, indicating pen and needle preparation before injection.*

FDA Label Image

Fig. L (Image 11)

An instructional illustration showing how to select the dose on a Victoza injection pen. The image highlights a rotating dial to choose among three dose levels: 0.6 mg, 1.2 mg, and 1.8 mg, with 0.6 mg currently selected.*

FDA Label Image

Fig. M (Image 12)

Instructional illustration showing a hand holding a Victoza injection pen and turning the dose selector to set a dose of 0 mg, indicating how to adjust or prepare the injection pen before use.*

FDA Label Image

Fig. N (Image 13)

An instructional illustration showing a hand holding an injection pen pressed against the skin, with a downward arrow indicating injection direction and a stopwatch displaying the number 6, suggesting a 6-second wait time after injection.*

FDA Label Image

Fig. O (Image 14)

An instructional illustration depicting the needle of an injection pen pointing downward toward a surface, with a large blue arrow pointing upward beside it, suggesting movement or removal action related to the injection device.*

FDA Label Image

Fig. P (Image 15)

An illustration showing the removal of a protective cap from the needle of a prefilled injection pen. A large blue arrow points left, indicating the direction to pull off the cap. The image is likely part of an instruction for subcutaneous injection preparation.*

FDA Label Image

Fig. Q (Image 16)

An instructional illustration showing hands preparing a Victoza (liraglutide) 6 mg/mL injection pen for subcutaneous use. The image depicts a step in the injection process where a protective cap or cover is being removed from the pen.*

FDA Label Image

Figure 5 (Image 20)

A cumulative incidence curve comparing patients with an event over time (months) between Victoza (liraglutide) and placebo groups. The y-axis shows the percentage of patients with an event, and the x-axis indicates time from randomization in months. The graph includes a hazard ratio (HR) of 0.87 with a 95% confidence interval [0.78; 0.97], suggesting lower event incidence in the Victoza group. Patient counts at risk for both groups over the study period are shown below the graph.*

FDA Label Image

Figure 3 (Image 21)

A line graph comparing mean HbA1c percentage over 52 weeks for Glimepiride and two doses of Victoza (liraglutide) at 1.2 mg and 1.8 mg. The x-axis represents time in weeks, and the y-axis represents mean HbA1c percentage. The graph shows a decrease for all groups initially, with Victoza 1.8 mg maintaining the lowest levels over time compared to Glimepiride and Victoza 1.2 mg.*

FDA Label Image

Label Image (Lbl500904503)

Victoza 6 mg/mL injection label from A-S Medication Solutions showing lot number and dosing instructions. The label indicates that each prefilled pen contains liraglutide injection, with a total of 18 mg per pen. It specifies subcutaneous use only and includes storage instructions not to freeze. The packaging is for 3 pens.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.